Literature DB >> 27426724

Toll-like receptor 4 promotes angiogenesis in pancreatic cancer via PI3K/AKT signaling.

Yunliang Sun1, Congshan Wu1, Jianxia Ma2, Yu Yang3, Xiaohua Man4, Hongyu Wu4, Shude Li4.   

Abstract

Deregulation of Toll-like receptor 4 (TLR4) is closely associated with the progression of various types of cancers, but its role in pancreatic carcinogenesis is unclear. This study aimed to investigate the role of TLR4 in the angiogenesis of pancreatic cancer and the underlying molecular mechanisms. The culture supernatant (conditioned medium) of PANC-1 cells after appropriate treatment was used for the treatment of HUVECs. The proliferation, migration and tube formation of HUVECs were assessed by MTT, Transwell and Matrigel, respectively. In pancreatic cancer tissues, TLR4, VEGF and CD31 were upregulated as determined by immunohistochemistry and the expression of TLR4 and VEGF was positively correlated with microvessel density as detected by CD31 staining. Activation of TLR4 signaling by LPS in PANC-1 cells resulted in increased VEGF and phosphorylation of AKT, which were abolished by TLR4 silencing with siRNA and PI3K/AKT signaling inhibitor LY294002. The conditioned medium from PANC-1 cells treated with LY294002 or transfected with TRL4 siRNA reduced the proliferation, migration and tube formation of HUVECs. In contrast, the conditioned medium from PANC-1 cells treated with LPS stimulated the proliferation, migration and tube formation of HUVECs, which was however significantly inhibited by pretreatment of PANC-1 cells with LY294002 or transfection with TRL4 siRNA. Our findings suggest TLR4 may promote angiogenesis in pancreatic cancer by activating the PI3K/AKT signaling pathway to induce VEGF expression.
Copyright © 2016. Published by Elsevier Inc.

Entities:  

Keywords:  Angiogenesis; PI3K/AKT signaling; Pancreatic cancer; Toll-like receptor 4; VEGF

Mesh:

Substances:

Year:  2016        PMID: 27426724     DOI: 10.1016/j.yexcr.2016.07.009

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  22 in total

1.  Dysbindin promotes progression of pancreatic ductal adenocarcinoma via direct activation of PI3K.

Authors:  Cheng Fang; Xin Guo; Xing Lv; Ruozhe Yin; Xiaohui Lv; Fengsong Wang; Jun Zhao; Quan Bai; Xuebiao Yao; Yong Chen
Journal:  J Mol Cell Biol       Date:  2017-12-01       Impact factor: 6.216

2.  MD2 blockage prevents the migration and invasion of hepatocellular carcinoma cells via inhibition of the EGFR signaling pathway.

Authors:  Yajun Qi; Qilu Fang; Qinglin Li; Haiying Ding; Qi Shu; Yan Hu; Wenxiu Xin; Luo Fang
Journal:  J Gastrointest Oncol       Date:  2021-08

3.  Exploration of the System-Level Mechanisms of the Herbal Drug FDY003 for Pancreatic Cancer Treatment: A Network Pharmacological Investigation.

Authors:  Ho-Sung Lee; In-Hee Lee; Kyungrae Kang; Sang-In Park; Minho Jung; Seung Gu Yang; Tae-Wook Kwon; Dae-Yeon Lee
Journal:  Evid Based Complement Alternat Med       Date:  2022-05-10       Impact factor: 2.650

Review 4.  Microbial-Derived Toll-like Receptor Agonism in Cancer Treatment and Progression.

Authors:  Eileena F Giurini; Mary Beth Madonna; Andrew Zloza; Kajal H Gupta
Journal:  Cancers (Basel)       Date:  2022-06-14       Impact factor: 6.575

5.  Endothelial immune activation programmes cell-fate decisions and angiogenesis by inducing angiogenesis regulator DLL4 through TLR4-ERK-FOXC2 signalling.

Authors:  Sheng Xia; Heather L Menden; Thomas R Korfhagen; Tsutomu Kume; Venkatesh Sampath
Journal:  J Physiol       Date:  2018-03-02       Impact factor: 5.182

Review 6.  The gut microbiota can be a potential regulator and treatment target of bone metastasis.

Authors:  Kelly F Contino; Hariom Yadav; Yusuke Shiozawa
Journal:  Biochem Pharmacol       Date:  2022-01-15       Impact factor: 5.858

7.  Direct Effects of Lipopolysaccharide on Human Pancreatic Cancer Cells.

Authors:  Roxanne L Massoumi; Yaroslav Teper; Soichiro Ako; Linda Ye; Elena Wang; O Joe Hines; Guido Eibl
Journal:  Pancreas       Date:  2021-04-01       Impact factor: 3.243

8.  The TLR4-Active Morphine Metabolite Morphine-3-Glucuronide Does Not Elicit Macrophage Classical Activation In Vitro.

Authors:  Samira Khabbazi; Nan Xie; Wenjun Pu; Yannick Goumon; Marie-Odile Parat
Journal:  Front Pharmacol       Date:  2016-11-17       Impact factor: 5.810

9.  Phospho-Akt overexpression is prognostic and can be used to tailor the synergistic interaction of Akt inhibitors with gemcitabine in pancreatic cancer.

Authors:  Daniela Massihnia; Amir Avan; Niccola Funel; Mina Maftouh; Anne van Krieken; Carlotta Granchi; Rajiv Raktoe; Ugo Boggi; Babette Aicher; Filippo Minutolo; Antonio Russo; Leticia G Leon; Godefridus J Peters; Elisa Giovannetti
Journal:  J Hematol Oncol       Date:  2017-01-06       Impact factor: 17.388

10.  Prediction of novel target genes and pathways involved in bevacizumab-resistant colorectal cancer.

Authors:  Precious Takondwa Makondi; Chia-Hwa Lee; Chien-Yu Huang; Chi-Ming Chu; Yu-Jia Chang; Po-Li Wei
Journal:  PLoS One       Date:  2018-01-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.